keyword
MENU ▼
Read by QxMD icon Read
search

Lawrence T Goodnough

keyword
https://www.readbyqxmd.com/read/27902502/zika-virus-and-patient-blood-management
#1
Lawrence T Goodnough, Marisa B Marques
Sporadic Zika virus infections had only occurred in Africa and Asia until an outbreak in Micronesia (Oceania) in 2007. In 2013 to 2014, several outer Pacific Islands reported local outbreaks. Soon thereafter, the virus was likely introduced in Brazil from competing athletes from French Polynesia and other countries that participated in a competition there. Transmission is thought to have occurred through mosquito bites and spread to the immunologically naive population. Being also a flavivirus, the Zika virus is transmitted by the Aedes mosquito that is endemic in South and Central America that is also the vector of West Nile virus, dengue, and chikungunya...
November 29, 2016: Anesthesia and Analgesia
https://www.readbyqxmd.com/read/27644011/patient-blood-management-as-standard-of-care
#2
Aryeh Shander, Arthur W Bracey, Lawrence T Goodnough, Irwin Gross, Nabil E Hassan, Sherri Ozawa, Marisa B Marques
No abstract text is available yet for this article.
October 2016: Anesthesia and Analgesia
https://www.readbyqxmd.com/read/27557476/national-and-international-guidelines-for-patient-blood-management-in-obstetrics-a-qualitative-review
#3
Ruth Shaylor, Carolyn F Weiniger, Naola Austin, Alexander Tzabazis, Aryeh Shander, Lawrence T Goodnough, Alexander J Butwick
In developed countries, rates of postpartum hemorrhage (PPH) requiring transfusion have been increasing. As a result, anesthesiologists are being increasingly called upon to assist with the management of patients with severe PPH. First responders, including anesthesiologists, may adopt Patient Blood Management (PBM) recommendations of national societies or other agencies. However, it is unclear whether national and international obstetric societies' PPH guidelines account for contemporary PBM practices. We performed a qualitative review of PBM recommendations published by the following national obstetric societies and international groups: the American College of Obstetricians and Gynecologists; The Royal College of Obstetricians and Gynecologists, United Kingdom; The Royal Australian and New Zealand College of Obstetricians and Gynecologists; The Society of Obstetricians and Gynecologists of Canada; an interdisciplinary group of experts from Austria, Germany, and Switzerland, an international multidisciplinary consensus group, and the French College of Gynaecologists and Obstetricians...
August 23, 2016: Anesthesia and Analgesia
https://www.readbyqxmd.com/read/26448376/how-do-i-implement-an-automated-screen-for-high-titer-abo-antibody-as-an-inventory-management-tool-for-abo-plasma-incompatible-platelets
#4
Magali J Fontaine, Jan Webster, Samantha Gomez, Tho D Pham, Lawrence T Goodnough, Susan A Galel
BACKGROUND: Plasma volume reduction (PVR) may reduce the risk of hemolysis associated with transfusion of plateletpheresis blood products (PLTs) containing ABO-incompatible plasma. But PVR may delay PLT issue. In collaboration with our blood donor center we evaluated an automated screen of PLT for high-titer ABO antibody and to apply PVR to high-titer PLTs. STUDY DESIGN AND METHODS: At the donor center, plasma from PLT donors was tested using an automated microplate system (PK7300, Beckman)...
December 2015: Transfusion
https://www.readbyqxmd.com/read/25812005/transfusion-and-coagulation-management-in-major-obstetric-hemorrhage
#5
REVIEW
Alexander J Butwick, Lawrence T Goodnough
PURPOSE OF REVIEW: Major obstetric hemorrhage is a leading cause of maternal morbidity and mortality. We will review transfusion strategies and the value of monitoring the maternal coagulation profile during severe obstetric hemorrhage. RECENT FINDINGS: Epidemiologic studies indicate that rates of severe postpartum hemorrhage (PPH) in well resourced countries are increasing. Despite these increases, rates of transfusion in obstetrics are low (0.9-2.3%), and investigators have questioned whether a predelivery 'type and screen' is cost-effective for all obstetric patients...
June 2015: Current Opinion in Anaesthesiology
https://www.readbyqxmd.com/read/25519751/how-i-use-fibrinogen-replacement-therapy-in-acquired-bleeding
#6
Jerrold H Levy, Lawrence T Goodnough
Fibrinogen is a critical protein for hemostasis and clot formation. However, transfusion guidelines have variable recommendations for maintaining fibrinogen levels in bleeding patients. An increasing number of studies support the practice of fibrinogen replacement therapy for acquired coagulopathies, and additional studies are underway. Fibrinogen therapy can be administered with cryoprecipitate or fibrinogen concentrates, and clinical practice varies according to their availability and licensing status. Fibrinogen concentrate therapy has been studied in animal models and clinical trials and supports the critical role of fibrinogen repletion in bleeding patients...
February 26, 2015: Blood
https://www.readbyqxmd.com/read/25081548/blood-utilization-and-hemoglobin-levels-in-cancer-patients-after-label-and-coverage-changes-for-erythropoiesis-stimulating-agents
#7
REVIEW
Hairong Xu, James A Kaye, Catherine W Saltus, Jeffrey Crawford, Eduard Gasal, Lawrence T Goodnough
A comprehensive literature search was performed to examine the influence of changes in erythropoietin-stimulating agent (ESA) label and reimbursement policies on utilization of red blood cell transfusions and patient hemoglobin levels in US cancer patients receiving chemotherapy or anemia management. Studies conducted in ESA-treated patients showed an increase in transfusion rates when comparing the post-intervention period with pre-intervention period (range of relative change: 15-125%). Results from studies conducted in patients receiving chemotherapy irrespective of anemia treatment were variable; single-institution-based studies tended to show a decrease in transfusion rates (range of relative change: -3...
October 2014: Expert Review of Hematology
https://www.readbyqxmd.com/read/24995770/restrictive-blood-transfusion-practices-are-associated-with-improved-patient-outcomes
#8
Lawrence T Goodnough, Paul Maggio, Eric Hadhazy, Lisa Shieh, Tina Hernandez-Boussard, Paul Khari, Neil Shah
BACKGROUND: Blood transfusion has been cited as one of the five most overutilized therapeutic procedures in the United States. We assessed the impact of clinical decision support at computerized physician order entry and education on red blood cell (RBC) transfusions and clinical patient outcomes at our institution. STUDY DESIGN AND METHODS: Clinical patient outcomes and RBC transfusions were assessed before and after implementation of a best practice alert triggered for transfusions when the hemoglobin level was higher than 7 g/dL for all inpatient discharges from January 2008 through December 2013...
October 2014: Transfusion
https://www.readbyqxmd.com/read/24931617/iron-deficiency-anemia-bridging-the-knowledge-and-practice-gap
#9
REVIEW
Aryeh Shander, Lawrence T Goodnough, Mazyar Javidroozi, Michael Auerbach, Jeffrey Carson, William B Ershler, Mary Ghiglione, John Glaspy, Indu Lew
Despite its high prevalence, anemia often does not receive proper clinical attention, and detection, evaluation, and management of iron deficiency anemia and iron-restricted erythropoiesis can possibly be an unmet medical need. A multidisciplinary panel of clinicians with expertise in anemia management convened and reviewed recent published data on prevalence, etiology, and health implications of anemia as well as current therapeutic options and available guidelines on management of anemia across various patient populations and made recommendations on the detection, diagnostic approach, and management of anemia...
July 2014: Transfusion Medicine Reviews
https://www.readbyqxmd.com/read/24688754/experience-with-intravenous-ferric-carboxymaltose-in-patients-with-iron-deficiency-anemia
#10
REVIEW
David B Bregman, Lawrence T Goodnough
Erythropoiesis may be limited by absolute or functional iron deficiency or when chronic inflammatory conditions lead to iron sequestration. Intravenous iron may be indicated when oral iron cannot address the deficiency. Ferric carboxymaltose (FCM) is a nondextran iron preparation recently approved in the United States for intravenous treatment of iron deficiency anemia (IDA) in adult patients with intolerance or unsatisfactory response to oral iron or with nondialysis-dependent chronic kidney disease. The full dose is two administrations of up to 750 mg separated by at least 7 days (up to 1500 mg total)...
April 2014: Therapeutic Advances in Hematology
https://www.readbyqxmd.com/read/24188691/perioperative-and-transfusion-outcomes-in-women-undergoing-cesarean-hysterectomy-for-abnormal-placentation
#11
Kathleen F Brookfield, Lawrence T Goodnough, Deirdre J Lyell, Alexander J Butwick
BACKGROUND: Women with placenta increta (PI) and placenta percreta (PP) are at high risk of obstetric hemorrhage; however, the severity of hemorrhage and perioperative morbidity may differ according to the degree of placental invasion. We sought to compare blood component usage and perioperative morbidity between women with PI versus PP undergoing cesarean hysterectomy (CH). STUDY DESIGN AND METHODS: We identified 77 women who underwent CH for PI or PP from the NICHD MFMU Network Cesarean Registry, which sourced data from 19 centers from 1999 to 2002...
June 2014: Transfusion
https://www.readbyqxmd.com/read/24117955/fibrinogen-as-a-therapeutic-target-for-bleeding-a-review-of-critical-levels-and-replacement-therapy
#12
REVIEW
Jerrold H Levy, Ian Welsby, Lawrence T Goodnough
Fibrinogen plays a critical role in achieving and maintaining hemostasis and is fundamental to effective clot formation. There is increasing awareness of the important role of fibrinogen as a key target for the treatment and prevention of acquired bleeding. Fibrinogen is the first coagulation factor to fall to critically low levels (<1.0 g/L) during major hemorrhage (normal plasma fibrinogen levels range from 2.0 to 4.5 g/L), and current guidelines recommend maintaining the plasma fibrinogen level above 1...
May 2014: Transfusion
https://www.readbyqxmd.com/read/24117533/improved-blood-utilization-using-real-time-clinical-decision-support
#13
Lawrence T Goodnough, Lisa Shieh, Eric Hadhazy, Nathalie Cheng, Paul Khari, Paul Maggio
BACKGROUND: We analyzed blood utilization at Stanford Hospital and Clinics after implementing real-time clinical decision support (CDS) and best practice alerts (BPAs) into physician order entry (POE) for blood transfusions. STUDY DESIGN AND METHODS: A clinical effectiveness (CE) team developed consensus with a suggested transfusion threshold of a hemoglobin (Hb) level of 7 g/dL, or 8 g/dL for patients with acute coronary syndromes. The CDS was implemented in July 2010 and consisted of an interruptive BPA at POE, a link to relevant literature, and an "acknowledgment reason" for the blood order...
May 2014: Transfusion
https://www.readbyqxmd.com/read/23963731/ferric-carboxymaltose-in-patients-with-iron-deficiency-anemia-and-impaired-renal-function-the-repair-ida-trial
#14
RANDOMIZED CONTROLLED TRIAL
Jane E Onken, David B Bregman, Robert A Harrington, David Morris, John Buerkert, Douglas Hamerski, Hussain Iftikhar, Roberto Mangoo-Karim, Edouard R Martin, Carlos O Martinez, George Edward Newman, Wajeh Y Qunibi, Dennis L Ross, Bhupinder Singh, Mark T Smith, Angelia Butcher, Todd A Koch, Lawrence T Goodnough
BACKGROUND: Iron-deficiency anemia in non-dialysis-dependent chronic kidney disease (NDD-CKD) frequently requires parenteral iron replacement, but existing therapies often require multiple administrations. We evaluated the efficacy and cardiovascular safety of ferric carboxymaltose (FCM), a non-dextran parenteral iron permitting large single-dose infusions, versus iron sucrose in patients with iron-deficiency anemia and NDD-CKD. METHODS: A total of 2584 participants were randomized to two doses of FCM 750 mg in one week, or iron sucrose 200 mg administered in up to five infusions in 14 days...
April 2014: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/23772856/a-multicenter-randomized-active-controlled-study-to-investigate-the-efficacy-and-safety-of-intravenous-ferric-carboxymaltose-in-patients-with-iron-deficiency-anemia
#15
RANDOMIZED CONTROLLED TRIAL
Jane E Onken, David B Bregman, Robert A Harrington, David Morris, Peter Acs, Bruce Akright, Charles Barish, Birbal S Bhaskar, Gioi N Smith-Nguyen, Angelia Butcher, Todd A Koch, Lawrence T Goodnough
BACKGROUND: Many patients receiving oral iron for iron deficiency anemia (IDA) cannot tolerate or fail to respond to therapy, and existing intravenous (IV) iron formulations often require repeated administrations. Ferric carboxymaltose (FCM), a nondextran IV formulation, permits larger single doses. STUDY DESIGN AND METHODS: We evaluated FCM versus oral iron in IDA patients. After 14 days of oral iron, 507 participants responding inadequately to oral iron (hemoglobin [Hb] increase <1 g/dL; Cohort 1) were assigned to Group A (two doses of FCM, 750 mg, 1 week apart) or Group B (oral iron, 325 mg, 3 × day for 14 additional days)...
February 2014: Transfusion
https://www.readbyqxmd.com/read/23710629/open-aortic-valve-replacement-in-a-patient-with-glanzmann-s-thrombasthenia-a-multidisciplinary-strategy-to-minimize-perioperative-bleeding
#16
Ahmad Y Sheikh, Charles C Hill, Lawrence T Goodnough, Lawrence L Leung, Michael P Fischbein
BACKGROUND: Glanzmann thrombasthenia (GT) is an autosomal recessive disorder in which the platelet (PLT) glycoprotein IIb/IIIa complex is either deficient or dysfunctional. In its most severe form, GT may result in spontaneous bleeding, although most cases are first detected in the setting of an invasive procedure. CASE REPORT: A 59-year-old male with Type I GT and a history of transfusion reactions to PLT infusions developed severe aortic stenosis secondary to bicuspid valve disease...
February 2014: Transfusion
https://www.readbyqxmd.com/read/23706802/alternatives-to-blood-transfusion
#17
REVIEW
Donat R Spahn, Lawrence T Goodnough
The use of alternatives to allogeneic blood continues to rest on the principles that blood transfusions have inherent risks, associated costs, and affect the blood inventory available for health-care delivery. Increasing evidence exists of a fall in the use of blood because of associated costs and adverse outcomes, and suggests that the challenge for the use of alternatives to blood components will similarly be driven by costs and patient outcomes. Additionally, the risk-benefit profiles of alternatives to blood transfusion such as autologous blood procurement, erythropoiesis-stimulating agents, and haemostatic agents are under investigation...
May 25, 2013: Lancet
https://www.readbyqxmd.com/read/23706801/concepts-of-blood-transfusion-in-adults
#18
REVIEW
Lawrence T Goodnough, Jerrold H Levy, Michael F Murphy
Recent progress has been made in the identification and implementation of best transfusion practices on the basis of evidence-based clinical trials, published clinical practice guidelines, and process improvements for blood use and clinical patient outcomes. However, substantial variability persists in transfusion outcomes for patients in some clinical settings--eg, patients undergoing cardiothoracic surgery. This variability could be the result of insufficient understanding of published guidelines; different recommendations of medical societies, including the specification of a haemoglobin concentration threshold to use as a transfusion trigger; the value of haemoglobin as a surrogate indicator for transfusion benefit, even though only changes in concentration and not absolute red cell mass of haemoglobin can be identified; and disagreement about the validity of the level 1 evidence for clinical practice guidelines...
May 25, 2013: Lancet
https://www.readbyqxmd.com/read/23706789/blood-management-transfusion-medicine-comes-of-age
#19
Lawrence T Goodnough
No abstract text is available yet for this article.
May 25, 2013: Lancet
https://www.readbyqxmd.com/read/23692505/successful-treatment-of-recurrent-hyperhemolysis-syndrome-with-immunosuppression-and-plasma-to-red-blood-cell-exchange-transfusion
#20
Erik J Uhlmann, Shalini Shenoy, Lawrence T Goodnough
BACKGROUND: Hyperhemolysis syndrome is a serious transfusion reaction mostly reported in association with sickle cell disease, characterized by destruction of both donor and host red blood cells (RBCs) by an unknown mechanism. CASE REPORT: A 21-year-old man with sickle cell disease and multiple prior transfusions received two phenotype-matched, compatible RBC units during a brief admission for pain crisis. He developed rapid-onset progressive anemia and hemoglobinuria...
February 2014: Transfusion
keyword
keyword
52761
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"